Trial Profile
Study on Single Nucleotide Polymorphisms of Functional Proteins determining Absorption, Metabolism, and Excretion of Edoxaban
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 04 Mar 2020
Price :
$35
*
At a glance
- Drugs Edoxaban (Primary)
- Indications Cardiovascular disorders; Stroke
- Focus Pharmacodynamics; Pharmacogenomic
- 02 Mar 2020 Planned End Date changed from 10 Feb 2018 to 30 Jun 2019.
- 02 Mar 2020 Status changed from recruiting to active, no longer recruiting.
- 31 Jan 2019 Status changed from not yet recruiting to recruiting.